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Abstract: Human milk provides optimal infant nutrition for early life development.
However, there are situations in which human milk feeding is not the most viable option
for infant nutrition. Some factors include maternal illness, lactation insufficiency, storage
complications, and time constraints. As a result, modern infant formula has become
a substitute or alternative when breastfeeding is not possible or is inadequate for infants.
In the optimal design of formula, many factors are considered in creating a product that is
safe and provides a nutritional profile either equivalent to human milk or in optimal
alignment with infant needs. Human milk composition serves as a reference for infant
formula formulation. The purpose of this literature review is to provide a synopsis of recent
advances in infant formula research in the past 5 years (2014–2018). Specifically, the breadth
of bioactive components of human milk that are not yet available in infant formulas and dose
optimization requirements in full-term infants are reviewed. The nutritional value of infant
formulas has been improved by adding functional bioactive ingredients such as choline,
strains of probiotics, and prebiotic oligosaccharides. There are considerable variations in the
composition of available infant formulas between manufacturers and across different coun-
tries. Formulas still generally lack important contents such as antibodies and exosomes that
are present in human milk. Some of the adverse health outcomes associated with formula
feeding as compared with human milk feeding are attributed to the different composition of
the foods. This literature review summarizes the most recent research aimed at advancing
infant formula composition to narrow the difference in health outcomes between human milk
and formula-fed infants.
Keywords: nutrition, neonate, pediatrics, infant formula, ganglioside, miRNA
Introduction
The American Academy of Pediatrics (AAP) and the World Health Organization
(WHO) recommend that infants are exclusively breastfed for 6 months after birth
for optimal growth and development and that infants should continue to breastfeed
up to 2 years along with complementary foods.1 In the case infants are not breastfed
and banked or donor milk may not be available, infant formula is the most adequate
food alternative.2,3 The health benefits of human milk consumption are greater than
those of infant formula due to the nutritional and bioactive components in human
milk that are absent in infant formula or not present in optimal concentration
relative to the infant stage of growth and development.4 In this context, bioactives
are compounds in diet that elicit physiologic effects in the consumer. Important
bioactives for newborn health may include whole bacterial or mammalian cells,
nanovesicles derived from cells, membrane fragments, or macromolecules. Despite
the shortcomings of infant formula, it serves as the most viable substitution for
human milk. Therefore, it benefits researchers, practitioners, and industry to
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develop a nutritionally adequate substitute for human milk
which can ensure similar acute and chronic health out-
comes compared to human milk feeding.
In consideration of adding novel bioactive agents to
infant formulas, human milk is used as a model. In gen-
eral, commercially available infant formula products are
nutritionally interchangeable and there is minimal evi-
dence to support that one infant formula is better than
another.5 The composition of infant formula has great
importance as it can have a significant impact on long-
term health.6 As a result, when knowledge on optimizing
infant nutrition progresses, industry is continuously adapt-
ing the composition of infant formula to align growth and
development outcomes in formula-consuming infants with
those seen in infants that consume human milk. These
changes can include alternative sources of bioactive ingre-
dients, consideration of dose optimization, or addition of
novel bioactives.
Literature reviews to date have primarily focused on
a specific bioactive in extensive detail or on particular
health outcomes related to infant milk formula composi-
tion. The purpose of this literature review is to provide
a comprehensive synopsis of recent advances in infant
formula research pertaining to the inclusion, or dose opti-
mization, of novel bioactives. Accordingly, a range of
clinical health outcomes are reviewed in relation to the
plethora of bioactives present, or being considered for
inclusion, in infant formulas.
Methods
JSTOR, Embase, MedlinePlus, and Pubmed bibliographic
databases of published scientific research were accessed
for this literature review. The following search terms were
used: infant nutrition, neonatal nutrition, baby formula,
infant formula, human milk, human breast milk, breast-
feeding, and [(human milk OR formula) AND (protein
content OR lactalbumin OR lactoferrin OR probiotics
OR prebiotics OR oligosaccharide OR essential fat OR
polyunsaturated fat OR omega-3 OR omega-6 OR choline
OR lutein OR ganglioside OR milk fat globule membrane
OR microRNA]. Peer-reviewed scientific research selected
for inclusion in this work was primarily human clinical
intervention studies and were published between 2014 and
2018. Other literature published before 2014 was included
in this work to provide scope, context, and background to
the bioactive agent topic subsections.
Novel Bioactives
Protein Content
Bioactive proteins in human milk provide immune protec-
tion, assist in digestive processes, contribute towards gut
development, and act as carriers for some nutrients.7
Human milk and infant formula may differ in protein
composition and concentration. Human milk provides
total protein needs and is rich in essential amino acids.8,9
Whereas commercially available infant formulas are typi-
cally made from bovine milk which has a much higher
total protein concentration.10 Some infant formula pro-
ducts have soy as the primary protein source in order to
address allergy to cow’s milk. This is less common, as in
the United States about 69% of infants consume cow’s
milk formula and only 12% consume soy formula.11
In order for infants to avoid drastically exceeding protein
requirements, the quantity and quality of protein in infant
formula should match closely to human milk. In infant for-
mula and human milk, higher protein content increases the
risk of infants being overweight and obese later in life.6,12
Rapid early growth during the first 2 years of life is asso-
ciated with the likelihood of being overweight and obese
during childhood.13 Recent formula products developed con-
tain lower protein concentrations with improved protein
quality.7 Recent clinical evaluations of infant formulas with
lowered protein content show that low-protein content for-
mula is safe and promotes adequate growth.14 Currently,
formulas meet protein requirements of 1.8–3.0 g/100 kcal
but there is no consensus on the optimal amount of protein in
infant formulas.15 In fact, the European Food Safety
Authority (EFSA) had proposed to lower the maximum
protein content of infant formula to reduce progressive
weight gain in formula-fed infants.16
Infant formula products generally contain adequate
protein concentrations that provide sufficient quantities of
all essential amino acids to meet the needs of developing
infants.17 However, protein concentrations in human milk
change over time as protein content is higher at the initial
stages of lactation and decrease during the later stages of
lactation. In earlier stages of lactation, human milk con-
tains 1.4–1.6 g protein/100 mL of protein. The concentra-
tion of protein lowers to 0.8–1.0 g/100 mL after 3 months
of lactation and to 0.7–0.8 g/100 mL after 6 months.1
These changes in human milk protein concentration over
the course of lactation necessitate consideration for opti-
mal age-specific products to provide adequate nutrition to
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infants at growth and development milestones before
being weaned.
α-Lactalbumin
α-Lactalbumin is a whey protein found in human milk at
a concentration of 28% of total protein and in bovine milk
at 3% of total protein.18 α-Lactalbumin provides essential
amino acids and the bovine form is added to infant
formulas.10 Since the introduction of α-lactalbumin to
infant formula, the proportion of α-lactalbumin has
increased in product over time since its structural elucida-
tion reveals it has a high proportion of tryptophan, lysine,
and cysteine; and is available and easily obtained from an
enriched whey protein fraction.19
α-Lactalbumin is bioavailable to the infant. It is digested
and absorbed and the oligopeptides and amino acids have been
shown to support critical immune functions such as phagocy-
tosis by macrophages and growth of Bifidobacteria.20,21 In
addition, the α-lactalbumin peptides are antimicrobial and
have shown activity in the colon against colonization of
Escherichia coli, K. pneumoniae, Staphylococcus aureus,
Staphylococcus epidermis, Streptococci, and Candida
albicans.22 Supplementation of α-lactalbumin in infant for-
mula containing a protein concentration of 1 g protein/
100 mL showed normal growth of infants up to 4 months of
age.23 This study demonstrates that the addition of α-
lactalbumin to infant formula supports a mechanism by
which total protein concentration of formula can be lowered,
the protein needs of the infant can still be met, and that growth
outcomes are still supported. Importantly, it has been shown
that α-lactalbumin does not affect iron absorption from for-
mula in infants. Since iron status can vary greatly depending
on weight and time of gestation in infants, research supports
the addition of a standard dose of α-lactalbumin to formula
with respect to iron requirement.24,25
Lactoferrin
Lactoferrin is a multifunctional whey protein found in
human milk that has antibacterial and antiviral properties;
it is involved in immune function, increased iron uptake,
and inhibition of carcinogenesis.26 The concentration is
variable in colostrum, but lactoferrin comprises 15–20%
of mature human milk protein content.10,27 The addition of
lactoferrin to formula from a bovine source is costly and
can exhaust raw product resources from cow milk contain-
ing only a very low quantity of the protein. Additionally, it
is difficult to preserve during infant formula production
due to denaturing at high temperatures.27,28
Commercially added lactoferrin has similar bioactive
properties as human lactoferrin. When lactoferrin was
added to infant formula, it was found that the incidence
of respiratory illnesses decreased while hematocrit
increased.27,29 However, enriched lactoferrin did not
improve iron absorption since bovine lactoferrin does not
bind to human lactoferrin receptors.30 Lactoferrin is
enriched in a small number of commercially available
infant formulas and is recognized as a safe ingredient by
the Food and Drug Administration.27,31 Even still, lacto-
ferrin is highly regulated to ensure it is of high quality
before its addition in infant formula.32 Furthermore, there
are still gaps in knowledge regarding an optimal dosage of
enriched lactoferrin in infant formula products.31
Probiotics
Probiotics are being added to infant formula and have been
shown to have multiple beneficial effects (Table 1). Probiotics
are microorganisms that can be present in human milk. The
most common strains include Staphylococci, Streptococci,
lactic acid bacteria, and Bifidobacteria.33 When consumed,
probiotics may influence the gut microbiota composition of
the infant which is colonized by over 1014 microorganisms.33
The intestinal microbiota aids in digestion, gut homeostasis,
immune function, and in maintaining stool firmness.33 When
probiotics are not consumed in human milk or formula, the
rates of negative health outcomes such as necrotizing entero-
colitis, infection, and underweight infants increase.33 During
infant development, the gut profile of microbiota is not static
and can be influenced by environmental factors like diet.33 The
method of delivery, length of gestation, and antibiotic use can
also change themicrobial composition of the gut.33 Thus, there
is interest in determining which strains could be consumed to
counteract deleterious environmental influences on gut micro-
biome composition.
Some infant formula manufacturers have started incor-
porating probiotics into products. Efficacy varies greatly
between strains of bacteria used; however, the use has
been shown to be safe even if there is no observable effect
on health outcomes.33–36 A study on infants less than 3
months old at enrollment who received Bifidobacterium
infantis IM1 in a dose of 107 colony-forming units (cfu)
per gram for 12 weeks had less incidence of diarrhea,
reduction in Proteobacteria in stool samples, and higher
stool frequency when compared to the control arm.35
Additionally, synbiotics, the use of both probiotics and
prebiotic, have shown additive beneficial effects. Research
on supplementing Bifidobacterium lactis and bovine milk-
Dovepress Skolnick et al
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derived oligosaccharides in formula for infants averaging 5
days old showed a reduction in the number of infants with
gastrointestinal infections and diarrhea.36 The evidence for
inclusion of probiotics in infant formula is convincing, and
future work should focus on which specific or combination
of strains should be included, the dosage, and whether live
cultures or lysed fragments are optimal for enhanced infant
health outcomes.
Prebiotics
Prebiotics are non-digestible oligosaccharides that stimu-
late the growth and function of bacteria in the gastroin-
testinal tract.33,37 Prebiotics are found in high
concentrations in human milk but are found only in trace
amounts in cow’s milk. Thus, it is imperative for product
manufacturers to fortify infant formulas with prebiotics
above and beyond the amount intrinsic in bovine milk in
order to elicit positive physiologic effects. Products are
most often supplemented with galacto-oligosaccharide,
fructo-oligosaccharide or polydextrose.37 These bioactive
prebiotics have been shown to increase the growth of
beneficial microorganisms like Bifidobacteria in the gut
and resilience of the gut microbiome to metabolic
stressors.37 The discrepancies in infection rates, stool pH,
and stool consistency between infants consuming human
milk and those fed formula are lessened when formula is
supplemented with prebiotics.37 Apart from allergy, possi-
ble side effects identified include bloating, abdominal
discomfort, and flatulence in doses of over 20 g/day in
infants up to 28 days old.33
Human Milk Oligosaccharides
Human milk oligosaccharides (HMO) are complex, non-
digestible carbohydrates that are found in human milk and
are not present in bovine milk.38 HMOs have many poten-
tial benefits for developing infants, and the biological roles
and functions of HMOs have been studied more exten-
sively only in recent years.38 More than 200 HMOs have
been discovered in human milk, where 2-fucosyllactose is
the predominant oligosaccharide as it comprises 20–30%
of HMOs.39 The functions, either additive or synergistic,
of all HMOs have not yet been elucidated. In addition, the
mechanism of action of most HMOs is unknown, but some
may function as prebiotics and stimulate the growth of
Bifidobacteria which colonize the infant gut and prevent
pathogen adhesion to mucosal surfaces to reduce risks of
infections.40 It has been shown that HMOs also support
gastrointestinal and immune functions and that there are
lower risks of viral infections in infants consuming HMOs
from human milk.41,42
When evidence for the addition of HMOs to formula
was scant, many producers added this bioactive to formu-
las simply because HMOs are found in human milk.43
Recently, research on HMO addition to infant formulas
revealed evidence showing that prebiotic-enriched for-
mula-fed infants display a profile of gastrointestinal
Table 1 Human Clinical Research on Health Outcomes Related to Inclusion of Probiotics in Infant Milk Formulae
Author, Year Region Participants Intervention Outcomes
Escribano et al, 201835 Spain Healthy, term newborns born
≥37 weeks of gestation, with
normal birth weight (3rd to 97th
percentiles for gestational age),
normal growth curve, ≤3 months
of age at enrollment; N=151
completed.
Double-blinded, randomized,
multicenter, controlled clinical
trial; infant formula
supplemented with 107 cfu/g of
B. infantis IM1 (experimental),
standard formula (control); 12-
week study.
Reduced diarrhea episodes and
lowered constipation prevalence
in experimental group.
Simeoni et al, 201636 Switzerland Full term, exclusively formula-fed
babies, mean age of 5 days;
N=115.
Randomized, double-blind,
control intervention; infant
formula supplemented with
a bovine milk oligosaccharide
(5.7 ± 1.0 g/100 g of powder
formula) and a B. lactis CNCM I-
3446 (107 cfu g/1 of powder
formula; experimental),
unsupplemented formula
(control); 12-week study.
1) Higher faecal pH and higher
diversity of faecal microbiota in
control group; 2) B. lactis
increased by 100-fold in the stool
and was detected in all infants in
the experimental group; 3)
Increased endogenous
Bifidobacteria (B. longum, B. breve,
B. bifidum, B. pseudocatenulatum)
in experimental group.
Skolnick et al Dovepress
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microbiota that is similar to breastfed infants.43 HMO-
supplemented infants do not have significant differences
in length, weight, and head circumference in comparison
to breastfed infants and non-prebiotic supplemented
infants.44 Prebiotic-supplemented infants have increased
frequencies of stool in comparison to human milk-fed
infants and stool pH levels equal to human milk-fed
infants.45
In a recent clinical study, it was found that infant
formula that is enriched with 2ʹfucosyllactose and lacto-
N-neotetraose is safe and supports adequate infant growth
and development. In addition, it was found that there is
lower incidence of bronchitis and medication use includ-
ing antipyretics and antibiotics among infants that were
fed HMO-supplemented formula.46 The addition of 2ʹ-
fucosyllactose and lacto-N-neotetraose has contributed
towards closing the compositional gap between human
milk and infant formula. It is anticipated that more
HMOs will be added to infant formula as it is safe for
infants and promotes beneficial health outcomes in early
life.47
Polyunsaturated Fatty Acids
Polyunsaturated fatty acids (PUFAs) have been added to
infant formula products to function as bioactive ingredi-
ents (Table 2) that aid in eye and brain development.
PUFAs have many biological effects on membrane func-
tion and composition, production of inflammatory media-
tors, and immune responses.4,48 A meta-analysis published
in 2012 showed that PUFA supplementation in infant for-
mulas did not have significant effects on improving early
infant cognition.49 However, intervention studies have
shown that PUFA supplementation has positive develop-
mental outcomes that resemble trajectories seen in infants
fed human milk with respect to cognitive function, visual
acuity, and immune response.50,51
Docosahexaenoic acid (DHA) and arachidonic acid (AA)
are PUFAs that are found in human milk and have important
roles in the development of plasma membrane constituents.5
DHA and AA are added to formula instead of the respective
n-6 and n-3 precursors since the elongation and desaturation
processes are slow and inefficient resulting in a very low
conversion rate. Infants that are fed formulas supplemented
with PUFAs have higher levels of DHA and AA in plasma or
red blood cells compared with infants that are breastfed or fed
formulas that are not supplemented.53,54 Infants that are fed
formulas that are fortified with DHA and AA have lower
incidences of upper respiratory infections and allergies,
bronchitis, nasal congestion, cough, diarrhea that requires
medical attention, atopic dermatitis, eczema, and contact
dermatitis.55–57
Although the concentration of n-6 and n-3 PUFAs in
human milk varies highly depending on maternal diet,52
there is insufficient data that supports the addition of DHA
to formula without AA as well.50 Infant formulas that
include AA and DHA have beneficial effects on the
immune system of developing infants. The absence of
AA in infant formula affects populations of circulating
T cells and macrophages and also causes an increase in
the presence of B cells expressing CD20+ and CD54+
activation markers compared to infant formula with
AA.58 The proportion of AA and DHA in supplemented
infant formula varies. Further research is needed to deter-
mine the exact dose and ratio of PUFAs for optimal
growth and development of humoral and cell-mediated
immunity.50
Choline
Choline is an essential bioactive micronutrient that plays
a role in cell signaling, structure of plasma membrane,
muscle function, and lipid transport. Choline is found in
human milk in a water-soluble form and is essential in
fetal cognitive development. The presence of choline alters
brain and spinal cord structure and function and can lower
risks of neural tube defects.59
The European Society for Pediatric Gastroenterology,
Hepatology and Nutrition recommends inclusion of no
more than 50 mg/100 kcal of choline in infant formula
products. Currently, there are no known cases of adverse
effects of having high choline intakes. Inadequate choline
levels can inhibit vitamin B12 and folic acid metabolism.
Current research on choline supplementation in infants
has been limited to preterm infants and more studies need
to be performed to examine its properties in infant
formula.
Lutein
Lutein is a carotenoid found in human milk and the concentra-
tion varies depending onmaternal diet, with intake of fruits and
vegetables increasing content.60 It functions as a structural
component of the eye, an antioxidant, and as a filter for blue
light. Lutein plays a biological and physiological role in the
visual development and function in infants;61 and infants are
reliant on breastfeeding to receive adequate quantities.62
Differences in serum lutein content between breastfed and
formula-fed infants are seen as early as 1 month of age.
Dovepress Skolnick et al
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Exclusively breastfed neonates had 6 times the average serum
lutein level in comparison to infants consuming formula. Even
in infants consuming formula fortified with lutein to
a concentration similar to human milk, serum levels were
drastically lower than in infants consuming human milk sug-
gesting a difference in bioavailability.63
Recent studies demonstrated that lutein-supplemented
infant formula is safe and supports the visual and cognitive
development of infants.60–62,64 Presently, there is no
research that lutein supplementation influences brain
accretion during infancy. A recent study found that the
concentration of lutein is higher in several regions of the
brain during infancy than in adulthood which may indicate
that lutein may play an important role in early neural
development.60 Currently, there are a number of infant
formulas that contain lutein. However, further research
on lutein must be conducted to ensure efficacy for optimal
growth and development outcomes in infants.61
Ganglioside
Gangliosides are sialylated glycosphingolipids commonly
found in the lipid membranes of cells. They play a large
Table 2 Human Clinical Research on Health Outcomes Related to Inclusion of Polyunsaturated Fatty Acids in Infant Milk Formulae
Author, Year Region Participants Intervention Outcomes
Makrides et al,
199553
Australia Infants born between 37–42 weeks
of gestation; mothers with no
history of lipid metabolism
disorders, insulin-dependent
diabetes, drug or alcohol abuse;
babies with appropriate weight for
gestation; N=79 completed.
Formula supplemented with fish oil
(experimental group), standard
unsupplemented formula (control);
30-week study.
1) Visual evoked potential was
improved in the experimental
group; 2) Erythrocyte DHA was
elevated in experimental group; 3)
Erythrocyte ARA was decreased in
experimental group.
Pastor et al,
200655
Spain Healthy infants, born after 36 weeks
gestation; N=1342.
Open label clinical trial; 2 groups:
formula with 34 mg AA and 17 mg
DHA (experimental) vs no added
AA/DHA or low amount ranging
from 6–13 mg AA and 8–16 mg
DHA (control); 12-month study.
1) Similar growth rates among
groups; 2) Treatment group had
lower incidence of bronchiolitis/
bronchitis vs control; 3) Lower
occurrence of rhinitis and lower
incidence of upper airway infection
in the experimental group vs control.
Lapillonne
et al, 201456
France Healthy, term infants born after 37
weeks of gestation, singleton, less
than 60 days of age at enrollment;
birth weight, length, and head
circumference appropriate for
gestational age (≥10th and ≤90th
percentile); N=325.
Multi-center clinical trial; infants
consumed formula with 17 mg DHA
and 34 mg ARA/100 kcal
(experimental) or with no added
DHA or ARA (control); duration of
study was until 1 year of age
1) Lower incidence of bronchitis,
croup, nasal congestion, cough in
experimental group; 2) Diarrhea that
required medical attention was
lower in experimental group; 3)
Odds ratio of increased number of
incidences of respiratory illness and
diarrhea was lower in experimental
group.
Foiles et al,
201657
USA Healthy infants, exclusively formula-
fed, singleton-birth, born between
37–42 weeks of gestation, birth
weight between 2490 and 4200
grams, ≤ 9 days old at time of
randomization; N=91.
Four-year follow-up on cohorts that
consumed formula supplemented
with PUFA (experimental) or
without PUFA (control).
1) Lower incidence of allergic
diseases and skin allergy in first year
of life in experimental group; 2)
Longer mean time until first allergic
illness in experimental group; 3)
Possible reduced risks of allergic
disease, wheezing, asthma in
experimental group.
Miklavcic et al,
201758
Canada Infants less than 21 days of age,
singleton birth, healthy, had body
weight, length, and head
circumference between the 10th and
90th percentile; N=89.
Prospective, double-blind controlled
study; formula containing 17 mg
DHA and 0, 25, or 34 mg ARA/100
kcal; 10-week study.
1) Plasma ARA level lower in group
consuming formula without ARA; 2)
Higher proportion of B cells and
activation markers in group
consuming formula without ARA.
Skolnick et al Dovepress
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role in neurological development, intracellular trafficking,
immune cell signaling, gut integrity, and preventing
infections.65,66 Gangliosides are present in human milk,
with disialoganglioside GD3 and monosialodihexosylgan-
glioside (GM3) being the primary molecular species.67
Total concentration of ganglioside is highest in early
stages of lactation and is predominantly comprised of
GD3. However, ganglioside GD3 content decreases over
period of lactation and GM3 becomes more prominent.67
In infant milk formulas the content of gangliosides is
provided from the bovine milk base, which has lower
ganglioside content than human milk.67 Supplementation
of infants with GD3 has shown beneficial effects on neu-
rologic development. Infants aged 2-8 weeks showed
increased Hand and Eye Coordination IQ, Performance
IQ, and General IQ on the Griffiths scales when formula
was supplemented with 2–3 mg of ganglioside/100 g of
infant formula.68 There is a case to be made for the addi-
tion of gangliosides to formula; however, very few studies
have been performed in human infants despite the
observed safety, tolerability, and efficacy of this bioactive.
MicroRNA
MicroRNA (miRNA) are bioactive components found in
human milk. They are small non-coding RNA molecules
that regulate the expression of genes involved in the cell
cycle, proliferation, differentiation, apoptosis, and the
immune response. It was recently discovered that
human milk contains various miRNAs that are bioavail-
able, circulate systemically, and are thought to be
involved in infant development.4,69 In addition to
human milk, bovine milk contains miRNA in an exo-
some vehicle for which bioavailability to human tissue
has been demonstrated utilizing an in vitro CaCo-2 cell
model, a human colorectal tumor cell line.70 There is
emerging research that miRNAs that are present in
human milk can enter phenotypically normal and
tumor cells and affect biological functions.69 Some
miRNAs found in bovine milk have similar nucleotide
sequences to those from human milk but analogous
effects have not been directly demonstrated.70
Currently, human and bovine milk miRNA are not
detected in many infant formulas.69 This may be due
to degradation of miRNA caused by homogenization
and heating of milk.70 Future research in this area
could consider whether bovine milk miRNAs are resis-
tant to processing steps in the production of infant
formulas, and whether human milk miRNA elicits phy-
siologic effects different from those of bovine miRNA.
Conclusion
This literature review summarizes research on the recent
advances in research related to the addition of novel
bioactive compounds to infant formula (2014–2018).
These advances consist of changing the source from
which certain ingredients or bioactives are derived,
altering the dose of bioactives, such as including speci-
fic protein in formula products, and adding novel bioac-
tive components like HMO and miRNA. Health
outcomes related to consumption of infant formula do
not emulate outcomes in infants that consume human
milk exclusively. However, adding bioactive ingredients
such as gangliosides, PUFA, and probiotics to infant
formulas achieves growth and developmental outcomes
in infants that are more in alignment with outcomes
observed in infants exclusively consuming human milk.
The addition of novel functional bioactive agents that
also promote health outcomes beyond growth, namely
immunity, cognition, and temperament, is of paramount
interest for future work. Currently, no uniform composi-
tion of bioactive compounds exists among commercially
available infant formulas. The optimization of infant
formula composition may be realized with more
research in longitudinal cohort studies following acute
and long-term health outcomes of children to ensure the
efficaciousness of novel bioactives.
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